Exchange: NASDAQ·Updated 07:35 PM EST
VCYT logo

VCYT Veracyte Inc

$25.18
$0.09
(0.36%)
Today
Closed $25.13
$0.05
(0.20%)
After Hours
Reported EarningsNov 4
Mkt Cap$2.03B
Vol2.79M

About VCYT

Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.
41

Bearish Sentiment

How do you feel about VCYT?

jskstocks
$VCYT 18-20 tomorrow if market tanks again. I got caught in this, but now I understand that their guidance is essentially eliminating growth in their fastest growing revenue stream..... That is why this may not be the bottom after all.
1
1
Mike__Cock
$VCYT Cathy Wood was buying this heavy. She buys high and sells low Jim Cramer and Cathy Wood what a pair.
3
epstok6789
$VCYT Load up! Overreact on future guidance. $100M repurchase program is good enough to buy. Cathie - thought she got the bargain, but bad timing screwed up her portfolio return.
2
epstok6789
$VCYT It is bottom when APLD is bottom. One with positive cash $370M on hand and $100M repurchase stock plan vs one with net loss -$221M and $6.4B debt. You will figure out which one will bottom or banckcrupt first to enter.
1
brijith86
$VCYT afterhour is gonna be more fun . Lets take it 18 and tomorrow to 15 keep shorting it easy money
1
SecoTrader
$VCYT after initial evaluation that looks a clear BUY in the mid term. I think they have just released the Q3 results on the worst possible day. I think the former valuation was probably a bit on the high end and a P/E ratio of 20-25 makes sense, so there is some room to go up I think. I bought some but unfortunately did not get right the bottom. Current average is 26.5$ with the possibility to buy more.
1
Mike__Cock
$VCYT offffff Cathy woodpecker been buying Time for Cathy and Cramer to form a partnership for a new etf called
1
whymystockmoved
$VCYT closed down 54.3% at $24.00 on Thursday (from $52.52), a day after its Q3 report. 1. Revenue +15% to $151.8M vs $147.1M expected; adjusted EPS $0.51 vs $0.41 (FactSet, via MT Newswires). 2. Decipher volume was about 29,900 tests, ~1,000 below plan; growth slowed from 24% to 17% to 12% over the year. Veracyte now expects 12,000 to 15,000 added tests a year, down from about 20,000. 3. First 2027 view: mid-single-digit revenue growth, adjusted EBITDA margin about 22% vs above 26% now. Leerink analyst Puneet Souda cut his rating to Market Perform ($35 target), raising the possibility of a structural decline; Veracyte's CEO says Decipher is still taking share and he is confident in the 12,000 figure. The catch: the article found no separate catalyst for the further fall after the open.
TheVoic
$VCYT the all time chart is ridiculous. Today's red candle is the longest in the available history
2Haflingers
$VCYT In a nutshell-Decipher is slowing down Decipher is Veracyte's prostate cancer diagnostic test and its largest revenue generator. - Decipher testing volume grew 12% year over year. - It performed below management's internal expectations for the second consecutive quarter. - It missed its quarterly volume target by approximately 1,000 tests. - Management lowered its expected annual incremental test volume from approximately 20,000 to 12,000–15,000.
Good2go
$VCYT Not in it but a 30% drop is impressive, or depressive as the case may be. Too much of a wild card for me and why I only trade biotech in ETFs when rarely getting the urge.
FlashMcGash
$VCYT reduced testing revenue $571M to $573M versus prior guidance of $576M to $582M, is not that much of a reduction....
leon_dedrick
$VCYT The stock was priced for massive growth............so any cut in guidance.. even one as small as this........demands a rerating from the market its brutal
StocktwitsEarnings
$VCYT Q3 '26 Earnings Results & Recap • Reported GAAP EPS of $0.51 • Reported revenue of $151.75M up 15.08% YoY • Veracyte now expects 2026 total revenue of $590M to $593M, representing 14% to 15% growth, testing revenue of $571M to $573M, and adjusted EBITDA margin greater than 26%.
TheVoic
$VCYT 👍 I've got a few spec shares about 15-20% up...if I buy more, it's going to crash...so I just keep my souvenir position 😂

Advertisement|Remove ads.